Clinical Research Directory
Browse clinical research sites, groups, and studies.
Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan
Sponsor: Virginia Commonwealth University
Summary
To determine feasibility of recruitment and tolerability of treatment with sacubitril-valsartan among adult age survivors of cancer diagnosed at or before age 39 who have stage B heart failure.
Official title: Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan (Treat HF)
Key Details
Gender
All
Age Range
18 Years - 120 Years
Study Type
INTERVENTIONAL
Enrollment
53
Start Date
2022-08-11
Completion Date
2028-11-30
Last Updated
2026-03-13
Healthy Volunteers
No
Conditions
Interventions
Sacubitril-valsartan
Administered orally twice daily at a maximally tolerate dose (max dose 97mg/103mg twice daily).
Valsartan
Administered orally twice daily at a maximally tolerate dose (max dose 160mg twice daily)
Locations (1)
Virginia Commonwealth University
Richmond, Virginia, United States